BTG 1640

Drug Profile

BTG 1640

Alternative Names: ABIO-08/01; ABIO-0801; BTG-1640

Latest Information Update: 31 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Reading
  • Developer Abiogen Pharma
  • Class Anxiolytics; Isoxazoles; Nootropics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Generalised anxiety disorder; Panic disorder

Most Recent Events

  • 02 Aug 2010 ABIO 08/01 is still in phase II trials for Panic disorder in Italy
  • 23 May 2008 Phase-II clinical trials in Panic disorder in Italy (PO)
  • 18 Mar 2008 This compound is still in phase II trials for Anxiety disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top